NASDAQ:OKYO OKYO Pharma Q4 2026 Earnings Report $1.50 -0.04 (-2.60%) Closing price 04:00 PM EasternExtended Trading$1.50 0.00 (0.00%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast OKYO Pharma EPS ResultsActual EPSN/AConsensus EPS -$0.04Beat/MissN/AOne Year Ago EPSN/AOKYO Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOKYO Pharma Announcement DetailsQuarterQ4 2026Date8/10/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(20-F) OKYO Pharma Earnings HeadlinesCritical Review: Akari Therapeutics (NASDAQ:AKTX) vs. OKYO Pharma (NASDAQ:OKYO)August 22 at 2:29 AM | americanbankingnews.comOKYO Pharma Announces Purchase of Shares by Chief Scientific OfficerJuly 28, 2026 | globenewswire.comA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.August 24 at 1:00 AM | Awesomely (Ad)OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026July 27, 2026 | globenewswire.comOKYO Pharma Announces Purchase of Shares by DirectorJuly 23, 2026 | globenewswire.comOKYO Pharma Announces Purchase of Shares by Chief Executive OfficerJuly 23, 2026 | globenewswire.comSee More OKYO Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OKYO Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OKYO Pharma and other key companies, straight to your email. Email Address About OKYO PharmaOKYO Pharma (NASDAQ:OKYO) Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis. Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease. The company’s second program, OK-202, is advancing in preclinical studies for chronic graft-versus-host disease, with plans to expand into other fibrotic indications. These programs leverage the company’s expertise in biologics engineering to deliver enhanced therapeutic profiles, including improved half-life and tissue targeting. Founded through a combination of biotechnology collaborations and strategic financing, Okyo Pharma completed its initial public offering on the NASDAQ under the ticker symbol OKYO. Headquartered in the United States, the company has established research partnerships across North America and Europe to support its clinical development efforts. Leadership is headed by Chief Executive Officer Thomas Baum, Ph.D., who brings extensive experience in biologics development and regulatory strategy.View OKYO Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersMongoDB Is Surging—And the Next Catalyst Is Almost Here5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's WhyMarketBeat Week in Review – 08/17 - 08/21BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish SetupFlash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Upcoming Earnings Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
